Assertio Therapeutics, INC (ASRT)

[ALERTS100%to10000%GAIN]

Assertio said the sale of Gralise allows it to focus on its growth products, Cambia and Zipsor, further strengthens its balance sheet, and increases its flexibility for future business development opportunities.
Alvogen is paying Assertio a total value of $127.5 million, including $75 million in cash upon closing and the balance payable in the form of a royalty on the first $70 million in Gralise sales. Both companies expect the majority of the royalties to be paid in the first calendar year.